CAS 252875-61-9 MAGEA4(230-239)

Send Inquiry
CAS 252875-61-9 MAGEA4(230-239)
Details
Cancer-testis antigen MAGE-A4 residues 230-239;
Category: Cancer-testis antigen / CTL epitope.
Peptide Purity (HPLC) ≥95%
CAS No. 252875-61-9
Structure Linear 10-mer (MAGE-A4 230-239)
Solubility DMSO/water cosolvent, PBS
Storage Powder, −20°C, dry, light-protected
Category
Epitope Peptides
Share to
Description

Shanghai Sonyt Biotechnology Co., Ltd. is one of the leading manufacturers and suppliers of cas 252875-61-9 magea4(230-239) in China, also supports custom service. Welcome to wholesale bulk high quality cas 252875-61-9 magea4(230-239) from our factory. Contact us for more details.

 

Description MAGE-A4 residues 230–239, an HLA-restricted CD8+ epitope; MAGE-A4 is a solid-tumor target for vaccines and TCR-T/CAR-T.

 

Product Basic Information Table

 

Product Standard English Name Product Abbreviation / Alias Function Tags (comma-separated) Core Structure Molecular Formula Exact Mass (Da) Average MW (Da) Salt Form Length (aa)
MAGE-A4 (230-239) peptide (GVYDGREHTV, 10-mer, HLA-A2 CTL epitope) MAGE-A4 230-239; GVYDGREHTV; MAGE-A4 p230-239; MAGEA4 epitope peptide cancer-testis antigen, MAGE-A4, HLA-A2, CD8+ T cell epitope, CTL epitope, cancer vaccine, TCR-T target, bispecific T cell engager, lung cancer, esophageal cancer, ovarian cancer, head and neck cancer, melanoma, immunogenic peptide Full sequence H-Gly-Val-Tyr-Asp-Gly-Arg-Glu-His-Thr-Val-OH; single-letter GVYDGREHTV, 10 aa; free N-terminal amine and free C-terminal carboxyl (free acid); linear peptide, no artificial modifications. Sensitive residues: Tyr x1 (light-sensitive oxidation), His x1, Arg x1; no free Cys, no Met, no Trp. C48H73N15O17 1131.53 1132.20 powder; typically TFA salt (residual TFA from RP-HPLC); CAS listed as free peptide; confirm on COA 10

 

Physicochemical Solubility & Storage Parameters

 

Product Code Appearance Long-term Storage Short-term Storage Solution Stability Solid Powder Stability
PEP-MAGEA4-01 White to off-white powder Store desiccated, light-protected and sealed at <= -20 C; expected powder stability 2-3 years After reconstitution, aliquot into single-use portions and store at -80 C; avoid repeated freeze-thaw (use within ~1 month) Protect from light due to Tyr. The peptide is relatively hydrophilic (Asp/Glu/Arg/His); soluble in sterile water or PBS, with a small amount of DMSO if needed; gentle sonication helps dissolution. Keep the powder dry, light-protected and sealed. With no free thiol or methionine, oxidation risk is low, but prolonged moisture uptake should still be avoided.

 

Functional Description

 

Product Code Frontend Short Summary Detailed Biological Function Description Applicable Research Areas (comma-separated) Targets / Receptors
PEP-MAGEA4-01 MAGE-A4 (230-239) peptide (CAS 252875-61-9) is the decapeptide GVYDGREHTV derived from melanoma-associated antigen MAGE-A4 (P43358). It is the classic HLA-A2-restricted CD8+ CTL epitope and the core target peptide of MAGE-A4-directed TCR-T and bispecific T-cell-engaging therapies. MAGE-A4 (melanoma-associated antigen 4, gene MAGEA4, UniProt P43358) belongs to the MAGE-I cancer-testis antigen family. It is essentially absent from normal somatic tissues but frequently expressed in lung (~51%), esophageal (~63%), ovarian, head-and-neck squamous, bladder carcinomas and melanoma, conferring strict tumor specificity. The decapeptide GVYDGREHTV (residues 230-239) was first identified by Dufour et al. in 1999 through autologous CTL cloning; presented by HLA-A2 (A*0201), it is recognized by MAGE-A4-specific CD8+ cytotoxic T lymphocytes that lyse HLA-A2+ MAGE-A4+ tumor cells. This epitope is a central target for solid-tumor TCR-T therapy: engineered TCRs specific for the MAGE-A4 p230-239/HLA-A2 complex (e.g., afamitresgene autoleucel, afami-cel) have shown clinical activity in synovial sarcoma and ovarian cancer. The peptide is widely used for in vitro stimulation of MAGE-A4-specific CD8+ T cells, TCR discovery, tetramer production and potency testing of TCR-T cells and peptide-HLA-targeting TCR-like/bispecific reagents. tumor immunology, cancer vaccine, T cell epitope mapping, HLA-A2 studies, TCR-T therapy, bispecific antibody, lung cancer, esophageal cancer, ovarian cancer, head and neck cancer, melanoma, synovial sarcoma, CTL killing assay, immune monitoring HLA-A2 / HLA-A*0201 (MHC class I); CD8+ TCR; MAGE-A4/P43358

 

 

 

 

Hot Tags: cas 252875-61-9 magea4(230-239), China cas 252875-61-9 magea4(230-239) manufacturers, suppliers, factory, 2293841-58-2, 265669-37-2, CAS 124454 83 7, CAS 199727 68 9, CAS 2293841 58 2, Nucleoprotein 118 126

Send Inquiry